Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

81.14 

-0.05 -0.1%

as of Oct 20 '20

52 Week Range:

69.10 95.19


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Sep '19 Dec '19
Equity (BVPS) 11.31
12.39
12.70
14.27
15.49
14.29
16.08
17.48
17.80
15.43
growth rate 9.6% 2.5% 12.4% 8.6% -7.8% 12.5% 8.7% 1.8% -6.9%
Earnings BIT 1,890.00
2,810.00
2,890.00
2,550.00
844.00
735.00
1,220.00
1,510.00
1,801.00
1,990.00
growth rate 48.7% 2.9% -11.8% -66.9% -12.9% 66.0% 23.8% 19.3% 5.1%
Avg.PE 21.19
12.76
15.92
18.98
15.14
22.33
5.61
51.52
24.00
0.00
18.00
growth rate -39.8% 24.8% 19.2% -20.2% 47.5% -74.9% 818.4% -53.4% -100.0%
ROA 8.15
12.17
11.79
8.70
9.64
4.13
27.19
4.39
9.92
5.92
growth rate 49.3% -3.1% -26.2% 10.8% -57.2% 558.4% -83.9% 126.0% -22.8%
ROE 20.64
33.82
34.40
26.13
30.12
11.41
57.95
8.23
19.20
12.77
growth rate 63.9% 1.7% -24.0% 15.3% -62.1% 407.9% -85.8% 133.3% -18.5%
ROIC 13.33
19.95
19.44
13.86
14.91
6.61
37.86
6.33
13.95
8.51
growth rate 49.7% -2.6% -28.7% 7.6% -55.7% 472.8% -83.3% 120.4% -21.9%
Cur. Ratio 1.98
1.78
1.95
1.69
1.71
2.05
2.40
2.57
2.09
2.32
growth rate -10.1% 9.6% -13.3% 1.2% 19.9% 17.1% 7.1% -18.7% 5.4%
Quick Ratio 1.22
1.10
1.20
0.96
0.94
1.58
1.64
1.84
1.28
1.62
growth rate -9.8% 9.1% -20.0% -2.1% 68.1% 3.8% 12.2% -30.4% 12.5%
Leverage 2.66
2.90
2.94
3.06
3.19
2.37
1.88
1.88
2.01
2.31
growth rate 9.0% 1.4% 4.1% 4.3% -25.7% -20.7% 0.0% 6.9% 7.2%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Sep '19 Dec '19
Acct.Receivable 2,265.00
2,715.00
2,769.00
3,415.00
1,884.00
1,731.00
1,691.00
1,793.00
1,840.00
1,814.00
1,896.00
growth rate 19.9% 2.0% 23.3% -44.8% -8.1% -2.3% 6.0% 2.6% -1.4% 4.5%
Acct.Payable 4,411.00
4,409.00
4,208.00
677.00
716.00
791.00
920.00
998.00
892.00
growth rate -0.1% -4.6% -83.9% 5.8% 10.5% 16.3% 8.5% -5.5%
Cur.Assets 7,989.00
8,650.00
9,260.00
10,195.00
10,162.00
11,796.00
6,574.00
7,263.00
5,959.00
7,210.00
7,503.00
growth rate 8.3% 7.1% 10.1% -0.3% 16.1% -44.3% 10.5% -18.0% 21.0% 4.1%
Total Assets 17,489.00
19,073.00
20,390.00
25,224.00
26,138.00
20,962.00
15,546.00
17,111.00
15,720.00
17,299.00
18,193.00
growth rate 9.1% 6.9% 23.7% 3.6% -19.8% -25.8% 10.1% -8.1% 10.0% 5.2%
Cash 2,685.00
2,905.00
3,270.00
2,733.00
2,925.00
2,213.00
2,801.00
3,394.00
1,838.00
3,009.00
3,335.00
growth rate 8.2% 12.6% -16.4% 7.0% -24.3% 26.6% 21.2% -45.9% 63.7% 10.8%
Inventory 2,371.00
2,628.00
2,803.00
3,499.00
1,577.00
1,604.00
1,430.00
1,475.00
1,667.00
1,715.00
1,653.00
growth rate 10.8% 6.7% 24.8% -54.9% 1.7% -10.9% 3.2% 13.0% 2.9% -3.6%
Cur.Liabilities 4,041.00
4,857.00
4,759.00
5,248.00
6,037.00
5,750.00
2,744.00
2,821.00
2,814.00
2,611.00
3,230.00
growth rate 20.2% -2.0% 10.3% 15.0% -4.8% -52.3% 2.8% -0.3% -7.2% 23.7%
Liabilities 10,922.00
12,488.00
13,452.00
16,761.00
17,982.00
12,097.00
7,266.00
7,995.00
7,854.00
9,682.00
10,281.00
growth rate 14.3% 7.7% 24.6% 7.3% -32.7% -39.9% 10.0% -1.8% 23.3% 6.2%
LT Debt 4,363.00
4,749.00
5,580.00
8,126.00
7,331.00
3,922.00
2,779.00
3,509.00
3,408.00
4,807.00
growth rate 8.9% 17.5% 45.6% -9.8% -46.5% -29.1% 26.3% -2.9% 18.8%
Equity 6,567.00
6,585.00
6,938.00
8,463.00
8,120.00
8,846.00
8,290.00
9,124.00
7,844.00
7,588.00
7,882.00
growth rate 0.3% 5.4% 22.0% -4.1% 8.9% -6.3% 10.1% -14.0% -3.3% 3.9%
Common Shares 594.00
573.00
556.00
549.00
547.00
549.00
551.00
555.00
546.00
520.00
519.00
growth rate -3.5% -3.0% -1.3% -0.4% 0.4% 0.4% 0.7% -1.6% -4.8% -0.2%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Sep '19 Dec '19
Capital Expenditures 963.00
960.00
1,161.00
706.00
925.00
911.00
719.00
616.00
659.00
696.00
growth rate -0.3% 20.9% -39.2% 31.0% -1.5% -21.1% -14.3% 7.0% 2.8%
Cash Dividends 688.00
709.00
804.00
1,023.00
1,095.00
910.00
268.00
315.00
376.00
423.00
growth rate 3.1% 13.4% 27.2% 7.0% -16.9% -70.6% 17.5% 19.4% 6.1%
Cash From OA 3,003.00
2,817.00
3,106.00
3,198.00
3,215.00
1,771.00
1,654.00
1,714.00
2,017.00
2,104.00
growth rate -6.2% 10.3% 3.0% 0.5% -44.9% -6.6% 3.6% 17.7% 2.1%
FCF per Share 3.43
3.38
3.50
2.94
2.45
0.24
1.39
2.58
2.11
2.13
growth rate -1.5% 3.6% -16.0% -16.7% -90.2% 479.2% 85.6% -18.2% 0.5%
Sale Purchase of Stock -1,135.00
-968.00
-405.00
369.00
193.00
286.00
347.00
growth rate 0.0% 0.0% 100.0% -47.7% 48.2% 21.3%
FCF 2,040.00
1,857.00
1,945.00
1,673.00
1,317.00
736.00
935.00
1,203.00
1,415.00
1,408.00
growth rate -9.0% 4.7% -14.0% -21.3% -44.1% 27.0% 28.7% 17.6% -0.3%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Sep '19 Dec '19
Sales 12,843.00
13,893.00
13,936.00
9,413.00
10,719.00
9,968.00
10,163.00
10,584.00
11,099.00
2,851.00
11,362.00
growth rate 8.2% 0.3% -32.5% 13.9% -7.0% 2.0% 4.1% 4.9% -74.3% 298.5%
Op.Income 2,136.00
2,224.00
2,283.00
315.00
844.00
735.00
1,220.00
1,510.00
1,801.00
1,990.00
growth rate 4.1% 2.7% -86.2% 167.9% -12.9% 66.0% 23.8% 19.3% 5.1%
IBT 1,890.00
2,809.00
2,838.00
375.00
490.00
428.00
4,954.00
1,100.00
1,617.00
481.00
970.00
growth rate 48.6% 1.0% -86.8% 30.7% -12.7% 1,057.5% -77.8% 47.0% -70.3% 101.7%
Net Income 1,420.00
2,224.00
2,283.00
315.00
2,497.00
968.00
4,965.00
602.00
1,546.00
369.00
1,001.00
growth rate 56.6% 2.7% -86.2% 692.7% -61.2% 412.9% -87.9% 156.8% -76.1% 171.3%
EPS 2.39
3.88
4.18
3.66
4.56
1.76
9.01
1.08
2.83
1.93
growth rate 62.3% 7.7% -12.4% 24.6% -61.4% 411.9% -88.0% 162.0% -17.4%
Gross Profit 5,958.00
7,046.00
7,134.00
4,162.00
4,634.00
4,156.00
4,306.00
4,585.00
4,811.00
4,916.00
growth rate 18.3% 1.3% -41.7% 11.3% -10.3% 3.6% 6.5% 4.9% 1.1%
R&D 915.00
946.00
1,081.00
582.00
608.00
589.00
566.00
615.00
618.00
542.00
growth rate 3.4% 14.3% -46.2% 4.5% -3.1% -3.9% 8.7% 0.5% -6.4%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 476.00
524.00
567.00
468.00
381.00
growth rate 10.1% 8.2% -17.5% -18.6%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 1,885.00
1,814.00
1,896.00
1,892.00
1,884.00
growth rate -3.8% 4.5% -0.2% -0.4%
Acct.Payable 2,494.00
2,426.00
892.00
2,478.00
2,529.00
growth rate -2.7% -63.2% 177.8% 2.1%
Cur.Assets 7,218.00
7,210.00
7,503.00
8,333.00
8,566.00
growth rate -0.1% 4.1% 11.1% 2.8%
Total Assets 17,544.00
17,299.00
18,193.00
19,075.00
19,465.00
growth rate -1.4% 5.2% 4.9% 2.0%
Cash 2,925.00
3,009.00
3,335.00
4,110.00
4,085.00
growth rate 2.9% 10.8% 23.2% -0.6%
Inventory 1,757.00
1,715.00
1,653.00
1,694.00
1,905.00
growth rate -2.4% -3.6% 2.5% 12.5%
Cur.Liabilities 2,597.00
2,611.00
3,230.00
3,036.00
2,880.00
growth rate 0.5% 23.7% -6.0% -5.1%
Liabilities 9,708.00
9,682.00
10,281.00
11,345.00
11,305.00
growth rate -0.3% 6.2% 10.4% -0.4%
LT Debt 5,136.00
5,105.00
4,807.00
6,222.00
6,272.00
growth rate -0.6% -5.8% 29.4% 0.8%
Equity 7,812.00
7,588.00
7,882.00
7,699.00
8,128.00
growth rate -2.9% 3.9% -2.3% 5.6%
Common Shares 683.00
683.00
683.00
683.00
683.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 154.00
153.00
191.00
172.00
144.00
growth rate -0.7% 24.8% -10.0% -16.3%
Cash Dividends 97.00
112.00
113.00
111.00
112.00
growth rate 15.5% 0.9% -1.8% 0.9%
Cash From OA 469.00
664.00
829.00
272.00
374.00
growth rate 41.6% 24.9% -67.2% 37.5%
Sale Purchase of Stock
growth rate
FCF 315.00
511.00
638.00
100.00
230.00
growth rate 62.2% 24.9% -84.3% 130.0%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 2,840.00
2,851.00
3,039.00
2,802.00
2,718.00
growth rate 0.4% 6.6% -7.8% -3.0%
Op.Income 476.00
524.00
567.00
468.00
381.00
growth rate 10.1% 8.2% -17.5% -18.6%
IBT 321.00
481.00
-223.00
378.00
289.00
growth rate 49.8% -100.0% 100.0% -23.5%
Net Income 308.00
369.00
-23.00
332.00
246.00
growth rate 19.8% -100.0% 100.0% -25.9%
EPS
growth rate
Gross Profit 1,212.00
1,255.00
1,341.00
1,195.00
1,075.00
growth rate 3.6% 6.9% -10.9% -10.0%
R&D 141.00
134.00
153.00
124.00
118.00
growth rate -5.0% 14.2% -19.0% -4.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (12.10)

YOY Growth Grade:

E (22.29)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 46.13 45.38 22.47
EPS / Growth -4.8% 1.79 10.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.0% 1.0%
Future PE 2.00 23.53 23.53
Future EPS 1.98 1.98 1.98
Value Price
MOS %
0.98
-98.8%
11.49
-85.8%
11.49
-85.8%
MOS Price 0.49 5.75 5.75
IRT 37.29 37.29 37.29

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.